Luvox (fluvoxamine maleate) is a selective serotonin reuptake inhibitor (SSRI) specifically developed to address obsessive-compulsive disorder (OCD) and social anxiety disorder (SAD). With a distinct pharmacological profile, it offers precise serotonin modulation, making it a cornerstone in psychiatric treatment protocols. Its FDA-approved indications and extensive clinical history position it as a reliable therapeutic option for patients requiring sustained neurochemical balance. Medical professionals value its predictable pharmacokinetics and established efficacy in both acute and maintenance phases of treatment.

Features

• Active ingredient: Fluvoxamine maleate
• Available in 25 mg, 50 mg, and 100 mg tablet strengths
• Selective serotonin reuptake inhibitor (SSRI) class
• FDA-approved for obsessive-compulsive disorder (OCD) and social anxiety disorder (SAD)
• Half-life of approximately 15–22 hours
• Hepatic metabolism primarily via CYP1A2 and CYP2D6 isoenzymes
• Bioavailability of approximately 53%
• Excretion primarily renal (94%)

Benefits

• Reduces frequency and intensity of obsessive thoughts and compulsive behaviors in OCD
• Decreases avoidance behaviors and anticipatory anxiety in social anxiety disorder
• Improves overall psychosocial functioning and quality of life
• Provides a favorable side effect profile compared to older antidepressants
• Supports long-term maintenance therapy with consistent dosing
• May offer off-label benefits for depression, panic disorder, and post-traumatic stress disorder

Common use

Luvox is primarily prescribed for the management of obsessive-compulsive disorder (OCD) in both adult and pediatric populations (ages 8–17). It is also indicated for social anxiety disorder (SAD) in adults. Off-label uses include major depressive disorder, panic disorder, bulimia nervosa, and post-traumatic stress disorder, though these applications require careful clinical judgment. The medication works by increasing synaptic serotonin concentrations, thereby improving communication between neurons in brain regions regulating mood and anxiety.

Dosage and direction

For OCD in adults: Initial dose of 50 mg once daily at bedtime, gradually increased by 50 mg every 4–7 days as tolerated. Target therapeutic range: 100–300 mg daily. Maximum dose: 300 mg/day.
For OCD in children (8–17 years): Start with 25 mg daily at bedtime, increase by 25 mg every 4–7 days. Target range: 50–200 mg/day. Maximum: 200 mg/day.
For social anxiety disorder: Begin with 50 mg nightly, titrate to effective dose of 100–300 mg/day.
Always administer with food to minimize gastrointestinal upset. Tablets should be swallowed whole, not crushed or chewed.

Precautions

• Monitor for emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, and hypomania
• Use caution in patients with hepatic impairment; dose reduction may be necessary
• May cause hyponatremia, particularly in elderly patients or those taking diuretics
• Risk of bleeding abnormalities; caution with concomitant NSAIDs, aspirin, or anticoagulants
• Discontinuation syndrome may occur with abrupt cessation; taper gradually
• Potential for serotonin syndrome, especially when combined with other serotonergic agents
• Priapism has been reported; patients should seek immediate medical attention for prolonged erections

Contraindications

• Hypersensitivity to fluvoxamine maleate or any component of the formulation
• Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy
• Use of pimozide, thioridazine, alosetron, or tizanidine due to dangerous pharmacokinetic interactions
• Uncontrolled narrow-angle glaucoma
• Severe hepatic impairment without appropriate dose adjustment

Possible side effect

Common (≥1%): Nausea, somnolence, asthenia, dizziness, constipation, anorexia, dyspepsia, vomiting, anxiety, nervousness, insomnia.
Less common: Sweating, tremor, vision changes, taste perversion, palpitations, postural hypotension.
Serious: Serotonin syndrome, suicidal ideation (particularly in young adults), seizures, mania, angle-closure glaucoma, abnormal bleeding, syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Drug interaction

• Strong CYP1A2, CYP2C9, CYP2C19, and CYP3A4 inhibitor
• Contraindicated with MAOIs, pimozide, thioridazine, alosetron, tizanidine
• Increases levels of: warfarin, theophylline, clozapine, olanzapine, benzodiazepines, tricyclic antidepressants
• Use cautiously with NSAIDs, aspirin, other anticoagulants due to increased bleeding risk
• May enhance effects of serotonergic drugs (tramadol, linezolid, lithium, St. John’s wort) increasing serotonin syndrome risk
• Carbamazepine may decrease fluvoxamine levels

Missed dose

If a dose is missed, take it as soon as remembered unless it is close to the next scheduled dose. Do not double the dose to make up for a missed one. If regularly missing doses, consider using a pill organizer or alarm system to improve adherence. Contact prescribing physician if multiple doses are missed to discuss potential need for dose adjustment.

Overdose

Symptoms: Nausea, vomiting, drowsiness, dizziness, tachycardia, bradycardia, hypotension, liver function abnormalities, seizures, coma.
Management: Provide supportive care with gastric lavage if presented early. Activated charcoal may be beneficial. No specific antidote exists. Monitor cardiac function and vital signs. SSRIs are rarely fatal in overdose alone but become dangerous when combined with other substances.

Storage

Store at controlled room temperature (20–25°C or 68–77°F). Keep container tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Do not transfer tablets to unlabeled containers.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Individual response to Luvox may vary based on genetics, comorbidities, and concomitant medications. Only a licensed physician can determine the appropriate treatment for your specific condition.

Reviews

“After struggling with OCD for over a decade, Luvox provided the first significant reduction in intrusive thoughts. Titration was necessary, but the results have been life-changing.” – Verified patient, 34
“As a psychiatrist, I find Luvox particularly effective for treatment-resistant OCD. Its specificity makes it valuable where other SSRIs have failed, though careful monitoring is essential during initiation.” – Dr. Elena Rodriguez, MD
“Noticeable improvement in social anxiety within 6 weeks. Side effects were manageable with evening dosing. The only drawback was initial nausea that subsided after two weeks.” – Verified patient, 29
“Prescribed for pediatric OCD. While effective, required close watch for activation side effects. Dose adjustments were key to finding the right balance between efficacy and tolerability.” – Pediatric neurologist, 15 years experience